Recent Updates
Recently added Catalysts
MYGN Positive Sentiment

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Key Takeaway: Myriad Genetics, Inc. is set to announce its third quarter earnings results for 2024 on November 7, 2024, following the market close. The earnings call will provide an overview of the company's performance and future guidance. Additionally, Myriad management is scheduled to participate in notable healthcare investor conferences later in November. This ongoing engagement indicates the company's commitment to transparency with its investors.
Price reaction · baseline $22.27 (2024-10-29 close) · hit after-hours · 2 other MYGN headline(s) in the window, move may be shared
day 0 close · peak
+2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Myriad Genetics is delivering earnings insights which may boost investor confidence.
  • The company continues to advance in genetic testing and precision medicine.
  • Participation in key investor conferences highlights active engagement with stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~41 mo
Minimal dilution risk
Lead asset
SKB264
Phase 2 · Solid Tumor

Full Press Release Details

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2024.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
Q4 Investor Conferences
Management will also be participating in the following investor healthcare conferences:
The Guggenheim Inaugural Global Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Wednesday, November 13, 2024 at 3:30 pm ET.
The 6th Annual Wolfe Research Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, and Sam Raha, Chief Operating Officer, on Wednesday, November 20, 2024 at 3:20 pm ET.
Live and archived webcasts of all presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Frequently Asked Questions

When will Myriad Genetics hold its Q3 earnings call?

Myriad Genetics will hold its Q3 earnings call on November 7, 2024, at 4:30 pm ET.

How can I access the earnings conference call?

The earnings call can be accessed via Myriad’s Investor Relations website or by phone after registration.

Who will represent Myriad at upcoming investor conferences?

Paul J. Diaz and Scott Leffler will represent Myriad at upcoming healthcare conferences.

What does Myriad Genetics specialize in?

Myriad Genetics specializes in genetic testing and precision medicine.

Where can I find more information about Myriad Genetics?

More information about Myriad Genetics is available at www.myriad.com.

Last updated: Oct 30, 2024